石药集团(01093.HK)普卢格列汀片获国家药监局批准上市

阿斯达克财经
13 Jan

石药集团(01093.HK) 公布,集团开发的化学药品1类新药普卢格列汀片(善泽平)已获中国国家药品监督管理局批准上市。

该产品是一种新型口服二肽基肽酶-IV(DPP-4)抑制剂,对DPP-4具有高选择性和强抑制性。产品适用于改善成人2型糖尿病患者的血糖控制,包括单药治疗和当单独使用盐酸二甲双胍仍不能有效控制血糖时的联合治疗。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10